Since anthracyclines are clinically used to treat multiple myeloma, acute myeloid leukemia, and hepatocellular carcinoma, ABCB1 may serve as a prognostic factor for the survival probability of patients affected with these tumor types. The gene discussed is ABCB1; the disease is plasma cell myeloma.